ÐÂÎÅÖÐÐÄ
News Center
ÖйúÉúÎïÖÆÒ©3¿î1ÀàÁ¢ÒìÒ©»ñÅúÁÙ´²£¬£¬ÁýÕÖÓÐÊý²¡/Ö×Áö/¹ýÃôÊг¡
Ðû²¼Ê±¼ä£º2025-04-08
¿ËÈÕ£¬£¬ÖйúÉúÎïÖÆÒ©£¨1177.HK£©ÏÂÊôÆóÒµÕý´óÌìÇç3¿î¿¹ÌåÀà1ÀàÁ¢ÒìÒ©——TQB2934£¨BCMA/CD3Ë«¿¹£©¡¢¡¢¡¢TQB2922£¨EGFR/c-MetË«¿¹£©¡¢¡¢¡¢TQC2938£¨ST2µ¥¿¹£©½ÓÁ¬»ñÅúÁÙ´²£¬£¬ÐÂÔö˳Ӧ֢»®·ÖΪÖÎÁƳÉÈËϵͳÐÔÇáÁ´Ð͵í·ÛÑù±ä¡¢¡¢¡¢ÁªºÏ¾³ÄÚÒÑÉÏÊÐÆäËû¿¹Ö×ÁöÒ©ÎïÖÎÁÆÍíÆÚ¶ñÐÔÖ×Áö¡¢¡¢¡¢ÖÎÁƼ¾½ÚÐÔ¹ýÃôÐÔ±ÇÑס£´ËÂÖ»ñÅúÁýÕÖÓÐÊý²¡/Ö×Áö/¹ýÃôÈý´ó¸ßÔöÌíÈüµÀ£¬£¬“Èý¼ýÆë·¢”ÔÙ¶ÈÕÃÏÔÆóÒµÑз¢ÊµÁ¦Ó븻ºñÔÚÑйÜÏß¡£
1.BCMA/CD3Ë«¿¹£º°ÐÏòÓÐÊý²¡“ALÐ͵í·ÛÑù±ä”
½¬Ï¸°ûÊÇÈËÌåÃâÒßϵͳµÄÖ÷Òª³ÉÔ±£¬£¬ËüÊÇÒ»¸ö“¿¹Ìå±ø¹¤³§”£¬£¬Í¨¹ýÊÍ·Å´ó×Ú¿¹ÌåÔÚÃâÒß·´Ó³ÖÐÊ©Õ¹Òªº¦×÷Ó᣿ÉÊÇ£¬£¬ÈôÊÇËüµÄ¿¹ÌåÉú²úÁ÷Ë®Ïß·ºÆðÒì³££¬£¬Éú²ú³ö´ó×Ú¹ýʧÕÛµþµÄ¿¹Ì壬£¬ÕâЩ¹ýʧ¿¹Ìå¾Í»á³Á»ýÔÚÈËÌåµÄÆ÷¹Ù×éÖ¯£¬£¬ÐγɼáÓ²µÄµí·ÛÑù°ß¿é£¬£¬×îÖÕµ¼ÖÂÆ÷¹ÙË¥½ß£¬£¬Õâ¾ÍÊǓϵͳÐÔÇáÁ´£¨AL£©Ð͵í·ÛÑù±ä”¡£ALÐ͵í·ÛÑù±äÊÇÓÐÊý²¡µÄÒ»ÖÖ£¬£¬·¢²¡ÂʽöΪ9-14Àý/100ÍòÉú³Ý/Ä꣬£¬¶à¼ûÓÚÍíÄêÈË[1]£¬£¬¸Ã²¡Æð²¡ÒþÄä¡¢¡¢¡¢ÁÙ´²ÌåÏÖ¶àÑù£¬£¬¿ÉÀÛ¼°ÉöÔà¡¢¡¢¡¢ÐÄÔàµÈ¶à¸öÆ÷¹Ù¡£
TQB2934ÊÇÕý´óÌìÇç×ÔÖ÷¿ª·¢µÄÁ¢ÒìÐÍ¿¹BCMA/CD3Ë«ÌØÒìÐÔ¿¹Ìå¡£Ñо¿ÏÔʾ£¬£¬ALÐ͵í·ÛÑù±ä»¼ÕߵĿË¡ÐÔ½¬Ï¸°ûÉÏĤÁ¬ÏµBCMA¸ß±í´ï£¬£¬Õï¶Ïʱ¹ÇËè±ê±¾ÖеĽ¬Ï¸°ûÖÐλBCMA±í´ïÂÊԼΪ65%£¬£¬¸´·¢Ê±½¬Ï¸°ûÖÐλBCMA±í´ïÂÊԼΪ75%¡£BCMA/CD3Ë«ÌØÒìÐÔ¿¹Ìåͨ¹ýÒ»¶ËÓëTϸ°ûÍâòµÄCD3ÊÜÌåÁ¬Ïµ£¬£¬ÁíÒ»¶ËÓë¿Ë¡ÐÔ½¬Ï¸°ûBCMAÁ¬Ïµ£¬£¬½«Tϸ°ûÕÐļÖÁBCMAÑôÐÔϸ°ûÖÜΧ£¬£¬½ø¶ø¼¤»îTϸ°ûÊÍ·Å¿ÅÁ£Ã¸¡¢¡¢¡¢´©¿×ËصÈɱÉËBCMAÑôÐԵİÐϸ°û¡£ÒÑÓÐÑо¿Åú×¢£¬£¬BCMA°ÐµãTϸ°ûÁÆ·¨ÖÎÁÆALÐ͵í·ÛÑù±ä£¬£¬»¼ÕßÓÐÍû»ñµÃÉî¶È»º½â[2]¡£ÏÖÔÚ£¬£¬È«Çò¹æÄ£ÄÚÉÐÎÞÖÎÁƸü²²¡µÄBCMA/CD3Ë«¿¹»ñÅú¡£
2.EGFR/c-MetË«¿¹£ºÁªºÏ·½°¸ÖÎÁÆÍíÆÚ¶ñÐÔÖ×Áö
EGFR£¨±íƤÉú³¤Òò×ÓÊÜÌ壩µÄ¹ý±í´ïÔÚÍ·¾±°©¡¢¡¢¡¢½áÖ±³¦°©¡¢¡¢¡¢ÒÈÏÙ°©ÒÔ¼°¸Î°©Ñù±¾ÖÐÆձ鱻·¢Ã÷£¬£¬ÓÈÆäÔÚ·ÇСϸ°û·Î°©£¨NSCLC£©ÖУ¬£¬³¬40%µÄNSCLC»¼ÕßÑù±¾Öмì²éµ½EGFRÌ«¹ý±í´ïºÍÒì³£¼¤»î¡£c-Met£¨¸Îϸ°ûÉú³¤Òò×ÓÊÜÌåc£©ÔÚ¶àÖÖÖ×ÁöÖб»·¢Ã÷£¬£¬ÆäÒì³£¼¤»îÔì³ÉHGF/c-MetÐźÅͨ·Òì³£»£»£»î»¯£¬£¬½ø¶øÔö½øÖ×Áöϸ°ûµÄÉú³¤¡¢¡¢¡¢ÇÖÏ®¡¢¡¢¡¢Ç¨áãºÍѪ¹ÜÐÂÉú[3]¡£±ðµÄ£¬£¬Ñо¿·¢Ã÷c-MetÒì³£ÓëEGFR TKIÄÍÒ©¹ØϵÇ×½ü£¬£¬ÊÇEGFR TKIÅÔ·ÄÍÒ©»úÖƵÄÒ»¸öÖ÷ҪƫÏò[4£¬£¬5]¡£
TQB2922ÊÇÒ»ÖÖ°ÐÏòEGFR/c-MetµÄÈËÔ´»¯Ë«ÌØÒìÐÔ¿¹Ì壬£¬Í¨¹ýÓëÖ×Áöϸ°ûÍâòEGFR¡¢¡¢¡¢c-MetÁ¬Ïµ×è¶ÏEGFR¡¢¡¢¡¢c-MetÐźÅͨ·¼¤»î£¬£¬½ø¶ø×èÖ¹Ö×ÁöÉú³¤ºÍÏ£Íû¡£Í¬Ê±£¬£¬TQB2922¿ÉÒÔͨ¹ý×ÔȻɱÉËϸ°û¡¢¡¢¡¢¾ÞÊÉϸ°ûµÈµÄ¿¹ÌåÒÀÀµÐÔϸ°û¶¾×÷Óü°¿¹ÌåÒÀÀµÐÔϸ°ûÍÌÊÉ×÷Ó㬣¬°ÐÏòÖ×Áöϸ°ûÍâòµÄEGFRºÍc-Met£¬£¬½ø¶øɱËÀÖ×Áöϸ°û¡£×ÛºÏTQB2922ÁÙ´²Ç°Ò©Àí¡¢¡¢¡¢¶¾ÀíÑо¿Ð§¹û£¬£¬ÒÔ¼°Í¬°ÐµãÒÑÉÏÊлòÔÚÑÐÒ©ÎïÓÅÒìµÄÁÙ´²Êý¾Ý£¬£¬TQB2922ÄâÁªºÏ¶àÖÖ¿¹Ö×ÁöÒ©ÎïÓÃÓÚÖÎÁÆ°üÀ¨·Î°©ÔÚÄÚµÄÍíÆÚ¶ñÐÔÖ×Áö£¬£¬Öª×ãÁÙ´²Î´±»Öª×ãµÄÖÎÁÆÐèÇó¡£
3. ST2µ¥¿¹£º×è¶Ï¹ýÃôÐÔ±ÇÑ׵ēÃâÒß¿ª¹Ø”
¹ýÃôÐÔ±ÇÑ×£¨AR£©×÷ΪÁÙ´²³£¼ûµÄÂýÐԱDz¡£¬£¬Ó°Ïì×ÅÈ«ÌìÏÂ10%-20%µÄÉú³Ý¡£ÎÒ¹ú×Ô2005 ÄêÊ״οªÕ¹³ÉÈËARÌìÏÂÊ¢Ðв¡Ñ§ÊÓ²ìºó£¬£¬2011ÄêÔٴοªÕ¹ÁËÌìÏÂ18ÆäÖÐÐijÇÊе绰ÎʾíÊӲ죬£¬ÏÔʾº£ÄÚ³ÉÈËARµÄ×Ô±¨»¼²¡ÂÊÒÑ´Ó2005ÄêµÄ11.1%ÉÏÉýµ½17.6%[6]¡£½üÄêÀ´£¬£¬ÃâÒßÖÎÁÆ×÷ΪARµÄÒ»ÏßÖÎÁÆÒªÁì[7],Òѱ»Ö¤Êµ¶ÔAR¾ßÓнüÆÚºÍÔ¶ÆÚ»ñÒ棬£¬ÇÒÓпÉÄÜÔ¤·ÀAR¿ªÕ¹ÎªÏø´£¬£¬ïÔ̱¬·¢ÐµÄÖÂÃô¡£
TQC2938ÊÇÒ»ÖÖ»ùÓÚÈËST2ÐòÁеÄÈËÔ´»¯IgG2µ¥¿Ë¡¿¹Ìå¡£Ñо¿ÏÔʾ£¬£¬ARÊÇÓÉTh1/Th2 µÄÃâÒßʧºâÒý·¢µÄ±äÓ¦ÐÔÑ×Ö¢·´Ó³£¬£¬AR»¼ÕߵıÇÇ»Éø͸ÎïÒÔ¼°ÑªÇåÖеÄIL-33ºÍST2µÄº¬Á¿ÏÔ×ÅÔöÌí£¬£¬ÇÒÓë¼²²¡µÄÑÏÖس̶ȳÊÕýÏà¹Ø¡£ÒÑÍê³ÉµÄ·ÇÁÙ´²ÊÔÑéÅú×¢£¬£¬TQC2938¿ÉÒÔÌØÒìÐÔÁ¬ÏµÈËST2£¬£¬Ã÷È·µØÒÖÖÆIL-33/ST2ÐźÅͨ·£¬£¬Í¨¹ýïÔÌÏÂÓÎTh2ϸ°ûÒò×ӵı¬·¢£¬£¬ÓÐÍû¸ÄÉƹýÃôÐÔ±ÇÑ×Ö¢×´¡£´Ë´ÎTQC2938ÐÂ˳Ӧ֢»ñÅúÁÙ´²£¬£¬ÄâÓÃÓÚ¼¾½ÚÐÔ¹ýÃôÐÔ±ÇÑ×£¨SAR£©¡£
²Î¿¼ÎÄÏ×£º
[1] Sanchorawala V. Systemic Light Chain Amyloidosis. N Engl J Med. 2024£»£»£»390£¨24£©:2295-2307.
[2] Forgeard N, et al. Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood. 2024£»£»£»143:734-737.
[3] ÕÅæÂ,³ÌÓêÀ¼,ÖܽðÅà,µÈ.ÒÔc-MetΪÖ×ÁöÖÎÁưеãµÄÊÜÌåÀÒ°±ËἤøÒÖÖƼÁµÄÑо¿Ï£Íû[J].ÖйúÒ©¿Æ´óѧѧ±¨,2015,46(01):16-27.
[4] Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J]. Science, 2007,316(5827):1039-043.
[5] Soh J,0kumura N,Lockwood WW,et al. Oncogene mutations,copy number gains and mutant allele specific imbalance(MASI)frequently occur together in tumor cells [J]. PLS One, 2009, 4(10):7464.
[6] Öйú±äÓ¦ÐÔ±ÇÑ×Õï¶ÏºÍÖÎÁÆÖ¸ÄÏ£¨2022Ä꣬£¬ÐÞ¶©°æ£©. Öлª¶ú±ÇÑʺíÍ·¾±Íâ¿ÆÔÓÖ¾57.02(2022):106-129.
[7] ¦ºè·É, ¹Ëè¤ÈØ, Íõ³É˶, µÈ. ±äÓ¦ÐÔ±ÇÑ×¹ýÃôÔÃâÒßÖÎÁÆÖйúÖ¸ÄÏ£¨2022ÄêÓ¢ÎÄÐÞ¶©°æ£©½â¶Á[J]. Öлª¶ú±ÇÑʺíÍ·¾±Íâ¿ÆÔÓÖ¾, 2023, 58(9): 847-853.
¡ø ÉÏÏ»¬¶¯Éó²é¸ü¶à
ÉùÃ÷£º
1.ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬·Ç¹ã¸æÓÃ;¡£
2.±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£
3.±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬²»¿ÉÒÔÈκη½Ê½È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬°üÀ¨Óйء¾TQB2934£¨BCMA/CD3Ë«¿¹£©¡¢¡¢¡¢TQB2922£¨EGFR/c-MetË«¿¹£©¡¢¡¢¡¢TQC2938£¨ST2µ¥¿¹£©¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢¡¢¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢¡¢¡¢ÉÌÒµ»¯Õ¹Íû¡¢¡¢¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£“Ô¤ÆÚ”¡¢¡¢¡¢“ÏàÐÅ”¡¢¡¢¡¢“¼ÌÐø”¡¢¡¢¡¢“¿ÉÄÜ”¡¢¡¢¡¢“Ô¤¼Æ”¡¢¡¢¡¢“ÆÚÍû”¡¢¡¢¡¢“ÓÐÍû”¡¢¡¢¡¢“ÍýÏ딡¢¡¢¡¢“ÍýÏ딡¢¡¢¡¢“DZÔÚ”¡¢¡¢¡¢“Ô¤²â”¡¢¡¢¡¢“Ô¤¼Æ”¡¢¡¢¡¢“Ó¦¸Ã”¡¢¡¢¡¢“½«”¡¢¡¢¡¢“Ä┡¢¡¢¡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÔ¤²â»òÆÚÍû£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢¡¢¡¢Ñз¢¡¢¡¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»ò·çÏÕµÄÓ°Ï죬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄ·çÏÕ£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢¡¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£